Generated by AI
Arvinas, Inc. is a clinical-stage biotechnology company focused on targeted protein degradation. The company develops therapies designed to harness the body’s natural protein disposal system to selectively degrade disease-causing proteins, using its proprietary PROTAC platform. Its current pipeline includes investigational programs in oncology and neuroscience, with candidates aimed at hormone-driven cancers, mutated cancers, lymphoma, and neurodegenerative disorders. Arvinas also advances collaboration-based programs alongside wholly owned assets, reflecting a business model centered on drug discovery, clinical development, and strategic partnerships. Headquartered in New Haven, Connecticut, Arvinas plays a notable role in the biopharmaceutical market as a developer of next-generation medicines intended to address difficult-to-treat diseases through a differentiated protein-degradation approach.
Website5 Science Park
New Haven, CT, 06511
United States
The latest articles about ARVN.
Summary of Oct 21's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of May 12's posts. Generated by AI.
Investors talking about ARVN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.